Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 4 1Phase 1/2 1Phase 1 1

Status

Recruiting 4Unknown 2Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 11INDUSTRY 11NIH 4

Study Type

Interventional 9Observational 2

Sponsor

Cancer Type

Gynecologic 67Breast 56Genitourinary 31Gastrointestinal 21Thoracic 18Sarcoma 14Tumor-Agnostic 11Head & Neck 10CNS 10Other solid neoplasm 7Lymphoid 5Dermatologic 4Classical hematology 4Plasma cell 2Other hematologic neoplasm 2NET 2Endocrine 2Myeloid 1

Conditions

Neoplasms 8Neoplasm Metastasis 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

11 trials
RecentStart dateEnrollment
OTHER × olaparib × Tumor-Agnostic × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05078671 2024-06-12

PROACTIVE

Radboud University Medical Center

Phase 4 Recruiting
160 enrolled
Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

University Hospital, Caen

Completed
200 enrolled
Tumor-Agnostic

Neoplasms

NCT01682772 2019-08-15

TOPARP

Institute of Cancer Research, United Kingdom

Phase 2 Unknown
148 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01491139 2012-05-30

ORCA

University College, London

Phase 1 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡